Company intelligence / Profile preview

MEDIPOST

Seongnam-si, Gyeonggi-do, South Koreaen.medi-post.co.kr ↗

Ownership: Public · 078160
Development stage: Commercial

Overview

MEDIPOST commercialized the world’s first regulatory-approved allogeneic human umbilical cord blood-derived mesenchymal stem cell product (CARTISTEM®) for knee osteoarthritis. Other programs are advancing through early clinical trials or preclinical development. The company has received over 33 public R&D grants and holds numerous patents related to its technologies

Therapeutic areas: PulmonologyNephrologyImmunologyRheumatology
Modalities: Umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs)allogeneic cell therapy
Industry: Biotech

Drug pipeline

11 assets

Cartistem

10 more assets in the full pipeline.

Request access →

Partnerships

Technology transfer agreement with LG Chemical for MLSC technology; other partnerships not detailed

Beyond the preview

Go deeper on MEDIPOST.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDIPOST.

Explore the full profile